News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,227 Results
Type
Article (40697)
Company Profile (270)
Press Release (677254)
Multimedia
Podcasts (76)
Webinars (17)
Section
Business (204572)
Career Advice (2019)
Deals (35508)
Drug Delivery (105)
Drug Development (81320)
Employer Resources (173)
FDA (16376)
Job Trends (14930)
News (346175)
Policy (32702)
Tag
Academia (2558)
Accelerated approval (28)
Adcomms (24)
Allergies (125)
Alliances (49574)
ALS (162)
Alzheimer's disease (1628)
Antibody-drug conjugate (ADC) (273)
Approvals (16598)
Artificial intelligence (456)
Autoimmune disease (119)
Automation (33)
Bankruptcy (361)
Best Places to Work (11638)
BIOSECURE Act (20)
Biosimilars (178)
Biotechnology (176)
Bladder cancer (147)
Brain cancer (52)
Breast cancer (595)
Cancer (4457)
Cardiovascular disease (367)
Career advice (1701)
Career pathing (34)
CAR-T (265)
CDC (44)
Celiac Disease (1)
Cell therapy (689)
Cervical cancer (35)
Clinical research (69100)
Collaboration (1484)
Company closure (4)
Compensation (1056)
Complete response letters (46)
COVID-19 (2698)
CRISPR (82)
C-suite (690)
Cystic fibrosis (136)
Data (5768)
Decentralized trials (2)
Denatured (25)
Depression (112)
Diabetes (462)
Diagnostics (6609)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (219)
Drug pricing (167)
Drug shortages (28)
Duchenne muscular dystrophy (213)
Earnings (89742)
Editorial (50)
Employer branding (21)
Employer resources (151)
Events (116633)
Executive appointments (938)
FDA (19189)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1335)
Gene editing (182)
Generative AI (38)
Gene therapy (545)
GLP-1 (921)
Government (4633)
Grass and pollen (6)
Guidances (376)
Healthcare (18858)
HIV (49)
Huntington's disease (39)
IgA nephropathy (75)
Immunology and inflammation (230)
Immuno-oncology (39)
Indications (78)
Infectious disease (2942)
Inflammatory bowel disease (180)
Inflation Reduction Act (13)
Influenza (104)
Intellectual property (216)
Interviews (315)
IPO (16624)
IRA (48)
Job creations (3640)
Job search strategy (1427)
Kidney cancer (15)
Labor market (79)
Layoffs (542)
Leadership (29)
Legal (7943)
Liver cancer (89)
Longevity (12)
Lung cancer (612)
Lymphoma (356)
Machine learning (37)
Management (59)
Manufacturing (687)
MASH (154)
Medical device (13693)
Medtech (13731)
Mergers & acquisitions (19865)
Metabolic disorders (1152)
Multiple sclerosis (144)
NASH (16)
Neurodegenerative disease (280)
Neuropsychiatric disorders (70)
Neuroscience (2728)
NextGen: Class of 2025 (6518)
Non-profit (4501)
Now hiring (61)
Obesity (532)
Opinion (248)
Ovarian cancer (152)
Pain (175)
Pancreatic cancer (200)
Parkinson's disease (257)
Partnered (31)
Patents (451)
Patient recruitment (412)
Peanut (54)
People (58550)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21533)
Phase II (30404)
Phase III (22685)
Pipeline (3989)
Policy (262)
Postmarket research (2564)
Preclinical (9167)
Press Release (64)
Prostate cancer (218)
Psychedelics (43)
Radiopharmaceuticals (267)
Rare diseases (723)
Real estate (5949)
Recruiting (69)
Regulatory (24028)
Reports (51)
Research institute (2375)
Resumes & cover letters (351)
Rett syndrome (23)
RNA editing (12)
RSV (73)
Schizophrenia (138)
Series A (220)
Series B (167)
Service/supplier (11)
Sickle cell disease (92)
Special edition (20)
Spinal muscular atrophy (153)
Sponsored (40)
Startups (3608)
State (2)
Stomach cancer (16)
Supply chain (99)
Tariffs (80)
The Weekly (49)
Vaccines (951)
Venture capital (76)
Weight loss (345)
Women's health (74)
Worklife (17)
Date
Today (50)
Last 7 days (209)
Last 30 days (1955)
Last 365 days (30186)
2025 (30122)
2024 (35219)
2023 (40076)
2022 (51175)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27328)
Location
Africa (734)
Alabama (77)
Alaska (7)
Arizona (291)
Arkansas (13)
Asia (38998)
Australia (6369)
California (10467)
Canada (3106)
China (993)
Colorado (439)
Connecticut (448)
Delaware (312)
Europe (84008)
Florida (1553)
Georgia (334)
Hawaii (2)
Idaho (61)
Illinois (791)
India (54)
Indiana (494)
Iowa (20)
Japan (382)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1312)
Massachusetts (7552)
Michigan (302)
Minnesota (592)
Mississippi (5)
Missouri (121)
Montana (30)
Nebraska (27)
Nevada (112)
New Hampshire (73)
New Jersey (2831)
New Mexico (28)
New York (2790)
North Carolina (1362)
North Dakota (8)
Northern California (5034)
Ohio (307)
Oklahoma (20)
Oregon (38)
Pennsylvania (2144)
Puerto Rico (19)
Rhode Island (45)
South America (1100)
South Carolina (59)
South Dakota (1)
Southern California (4052)
Tennessee (164)
Texas (1618)
United States (37423)
Utah (311)
Vermont (1)
Virginia (242)
Washington D.C. (78)
Washington State (860)
West Virginia (4)
Wisconsin (90)
Wyoming (2)
718,227 Results for "oragenics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
October 22, 2025
·
3 min read
Press Releases
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
July 17, 2025
·
4 min read
Press Releases
Oragenics Q2 2025 Shareholder Update
August 12, 2025
·
10 min read
Press Releases
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
May 13, 2025
·
3 min read
Press Releases
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
April 23, 2025
·
2 min read
Press Releases
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
April 8, 2025
·
1 min read
Deals
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share.
June 25, 2024
·
3 min read
BioMidwest
Oragenics, Inc. Announces Proposed Public Offering - June 24, 2024
Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that it intends to offer and sell shares of its common stock.
June 24, 2024
·
3 min read
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
Oragenics, Inc. today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.
May 17, 2024
·
3 min read
Drug Development
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
Oragenics, Inc. today announced an update on the company and its drug development program. Oragenics is designing an upcoming Phase II clinical trial conducted in acute and emergency departments.
May 16, 2024
·
5 min read
1 of 71,823
Next
